In the eBio agreement there are three parts to the payments of an upfront, FIXED REVENUE FOR MIX&GO RAGENT SUPPLIED, and a royalty fee paid quarterly.
So we can assume this increase is part of the supply monies
Under the terms of the agreement, Anteo will supply Mix&Go®™ for use in the manufacture of biological reagents for all applicable markets in which the company operates. Anteo will receive an initial upfront payment, fixed revenue for Mix&Go®™ reagent supplied, and a royalty fee paid quarterly based on a percentage of worldwide net sales.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)